M&A / Deals Bayer looks to uphold Eylea legacy with $2.45bn Perfuse buyout Pharmaceutical TechnologyIf approved, Perfuse's PER-001 could continue Bayer's ophthalmology legacy defined by blockbuster retinal disease therapy, Eylea.OphthalmologyRead full story pharminent May 6, 2026 (Last updated: May 6, 2026) Pharmaceutical Technology If approved, Perfuse’s PER-001 could continue Bayer’s ophthalmology legacy defined by blockbuster retinal disease therapy, Eylea. Ophthalmology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly inflates US facility investment spending by $4.5bnNext: Novo hikes guidance on Wegovy pill’s fast sales start Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
